Annual report pursuant to Section 13 and 15(d)

Shareholders' Equity (Tables)

v3.20.4
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Schedule of Anticipated and Actual Use of Net Proceeds
A summary of the anticipated and actual use of net proceeds used to date from the above financings is set out in the table below.
Allocation of net proceeds Total net proceeds from financings (in thousands) Net proceeds used to date (in thousands)
March 20, 2017 Offering
R&D Activities $ 123,400  $ 123,400 
Working capital and corporate purposes 38,924  38,924 
162,324  162,324 
November 30, 2018 ATM facility 28,830  28,830 
September 2019 ATM facility 14,371  14,371 
December 2019 Public Offering:
Pre-commercial and launch activities, working capital and corporate purposes 179,918  44,181 
July 2020 Public Offering:
Pre-commercial and launch related activities
$117,000 to $143,000
— 
R&D activities
$28,000 to $34,000
— 
Working capital and corporate purposes
10,500 to 42,500
— 
187,700  — 
Total $ 573,143  $ 249,706 
Summary of Outstanding Warrants and Warrants Outstanding
A summary of the outstanding warrants as of December 31, 2020 is presented below:
Number of Warrants
(in Thousands)
Weighted-Average
Exercise Price
$
Expiry date:
December 28, 2021 1,690 3.00
1,690 3.00
The warrant activity for 2019 and 2018 is as follows:
Number of Warrants
(in thousands)
Balance at December 31, 2018 3,523 
Warrants exercised (1,832)
Balance at December 31, 2019 1,691 
Warrants exercised (1)
Balance at December 31, 2020 1,690 
Schedule of Common Stock Outstanding Roll Forward
The common share activity for 2020, 2019 and 2018 is as follows:
Common Shares
Number of Shares
(in thousands)
Amount (in thousands)
Balance at December 31, 2017 84,052  $ 483,294 
Issued pursuant to exercise of warrants 1,172  3,977 
Issued pursuant to exercise of stock options 276  1,473 
Balance at December 31, 2018 85,500  488,744 
Issued pursuant to Public Offering 12,782  191,737 
Issued pursuant to At-the-Market (ATM) Facilities 6,953  45,010 
Share issue costs —  (13,629)
Issued pursuant to exercise of warrants 2,983  12,428 
Issued pursuant to exercise of stock options 3,580  22,197 
Balance at December 31, 2019 111,798  746,487 
Issued pursuant to Public Offering 13,333  200,000 
Share issue costs —  (12,268)
Issued pursuant to exercise of warrants
Issued pursuant to exercise of stock options 1,593  10,107 
Balance at December 31, 2020 126,725  $ 944,328